Manufacturing Sites

Medochemie has been steadily investing and expanding its Operations arm aiming to deliver high-level expertise, provide excellence and contribute in driving performance, increasing revenue, and enhancing the bottom line for all its Partners.


Our thirteen state-of-the-art manufacturing facilities are designed following the latest technology and fully comply with the current regulations for Good Manufacturing Practices (cGMPs) of the European Union and the World Health Organization (WHO). They are located in Cyprus, The Netherlands and Vietnam and can produce oral, parenteral and topical presentations, including penicillins, cephalosporins and dry powder inhalers.
Our AZ Factory in Cyprus, where 9 out of the 15 production sites are located, can produce and pack 1.5 billion tablets and 300 million capsules per year. Our injectables plant of cephalosporins is built online from the washing of the vials and sterilization units to the filling stage to rubber stoppering of the vials, capping, labeling and final packaging. We manufacture oral cephalosporins as well as oral and injectable penicillin’s in separate manufacturing plants.
Our dedicated respiratory products facility, Andi-Ventis, produces Dry Powder Inhalers (DPIs).
Our latest injectables manufacturing plant in Cyprus is for ampoules. It has a production and packing capacity of 100 million ampoules for injection per year.
In our factory in The Netherlands we manufacture oral dosage forms. We also sell dossiers to third parties for registration in EU and non-EU territories.
Medochemie Far East Ltd strategically located in Vietnam disposes 3 manufacturing facilities including:

  1. Oral facility (non-beta lactam) operating since May 2011 has a capacity of 2 billion tablets and 500 million capsules per year.
  2. Cephalosporin’s Injectable facility operating since June 2017 has a capacity of 55 million vials per year.
  3. Liquids & Semi-Solids facility operating since April 2018 has a capacity of 25 million bottles and 3 million tubes per year.

Our new Investment Project in the Southeast Asia region includes the addition of a production site for Injectable Beta lactams (dry powder for injection/infusion).